Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Triple therapy in diabetes, what’s the third line?

July 22nd 2011

When the NICE updated the clinical guideline for management of hyperglycaemia in 2009 (CG87) it reiterated the place of metformin and sulphonylureas as first- and second-line treatments respectively. However, what is recommended when dual therapy does not achieve HbA1c targets?

By default, NICE CG87 suggests that insulin is first choice for all patients by stating that oral agents should only be used when ‘insulin is unacceptable or inappropriate’. The insulin NICE recommends is human NPH with progression to long-acting analogues only in those experiencing hypoglycaemia or needing third party administration.

Where insulin is not used, oral agents may be considered for third line. Pioglitazone, having just survived an EMA review, is preferable in patients with ‘marked insulin insensitivity’ and in whom there is no increased risk of heart failure or bony fracture. Gliptins (although only sitagliptin has a triple therapy licence) are preferred where weight gain would ‘cause or exacerbate problems’. Both therapy classes should only be continued if they reduce the HbA1c by 0.5% in six months.

Another third line in patients with a BMI >35Kg/m2, GLP-1 injectables (exenatide and liraglutide) can be considered but need to achieve both an HbA1c reduction of 1% and weight loss of 3% in 6 months. Patients with lower BMIs may be eligible for GLP-1 if they would benefit from weight loss or lose their job if prescribed insulin.

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesAstraZenecaNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership